In the second quarter of 2012, Sanofi generated net sales of €8,870 million, up 6.2% on a reported basis. Exchange rate movements had a positive effect of 5.8 percentage points reflecting the appreciation of the U.S. dollar and, to a lesser extent, the appreciation of the Japanese Yen and Chinese Yuan against the Euro.

UCB has announced its consolidated half year 2012 financial results. The first half year was marked by continuous execution and growth of core medicines Cimzia® (certolizumab pegol), Vimpat® (lacosamide) and Neupro® (rotigotine) with combined net sales total exceeding EUR 413 million (+45%).

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012. Second-quarter 2012 revenues were $15.1 billion, a decrease of 9% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $977 million, or 6%, and the unfavorable impact of foreign exchange of $451 million, or 3%.

Sales of the Bayer Group grew by 10.0 percent in the second quarter, to EUR 10,177 million (Q2 2011: EUR 9,252 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 5.0 percent. The operating result (EBIT) fell by 41.1 percent to EUR 750 million (Q2 2011: EUR 1,273 million).

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

Amgen (NASDAQ:AMGN) announced financial results for the second quarter of 2012. Key results for the quarter include: Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio;

AstraZeneca revenue for the second quarter was $6,660 million, down 18 percent at constant exchange rates (CER). Revenue declined by 21 percent on an actual basis as a result of the negative impact of exchange rate movements.